Skip to main content
SpringerLink
Log in

When Results of T cell Immune Monitoring Match/Do Not Match Clinical Outcomes of Tumor Vaccine Trials: What More Could and Should We Measure?

  • Chapter
  • First Online:
The Tumor Immunoenvironment

  • 2155 Accesses

Abstract

Activation of cancer-specific T cells by tumor vaccines can lead to the rejection of the tumor. However, monitoring the tumor-specific T cell response continues to be a challenge. The magnitude and cytokine effector lineage of the vaccine-induced T cells, their ability to kill, and the avidity of the T cells for the tumor are among the primary parameters that define the T cell’s potential impact on the tumor. Due to determinant spreading, immunization with a tumor antigen can result in recruitment of T cells with specificity for unrelated antigens of the tumor. The efficacy of this second wave T cell repertoire will depend on clonal sizes, effector lineages, and their avidities for the tumor. Comprehensive immune monitoring should be able to measure all the above parameters of the primary and secondary T cell responses to the tumor. In this chapter, we propose an ELISPOT-based protocol which can help accomplish the above goal with reasonable cost and effort, requiring only 10 ml of patient blood.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Baars A, Claessen AM, van den Eertwegh AJ, Gall HE, Stam AG, Meijer S et al (2000) Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. Ann Oncol 11(8):965–970

    Article  PubMed  CAS  Google Scholar 

  • Barth RJ Jr, Fisher DA, Wallace PK, Channon JY, Noelle RJ, Gui J et al (2010) A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res 16(22):5548–5556

    Article  PubMed  CAS  Google Scholar 

  • Bartholomae WC, Rininsland FH, Eisenberg JC, Boehm BO, Lehmann PV, Tary-Lehmann M (2004) T cell immunity induced by live, necrotic, and apoptotic tumor cells. J Immunol 173(2):1012–1022

    PubMed  CAS  Google Scholar 

  • Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL et al (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24(34):5373–5380

    Article  PubMed  Google Scholar 

  • de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ et al (2005) Immuno monitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23(24):5779–5787

    Article  PubMed  Google Scholar 

  • Ding ZC, Zhou G (2012) Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol 2012:890178

    Article  PubMed  Google Scholar 

  • Disis ML (2011) Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 60(3):433–442

    Article  PubMed  CAS  Google Scholar 

  • Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL (2000) Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res 6(4):1347–1350

    PubMed  CAS  Google Scholar 

  • Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H et al (2009) Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 27(28):4685–4692

    Article  PubMed  CAS  Google Scholar 

  • Dittrich M, Lehmann PV (2012) Statistical analysis of ELISPOT assays. Methods Mol Biol 792:173–183

    Article  PubMed  CAS  Google Scholar 

  • Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L et al (2010) Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 59(5):663–674

    Article  PubMed  CAS  Google Scholar 

  • Hardwick N, Chain B (2011) Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients. Immunotherapy 3(6):731–733

    Article  PubMed  CAS  Google Scholar 

  • Hawkins N, Self S, Wakefield J (2006) The automated counting of spots for the ELISpot assay. J Immunol Methods 316(1–2):52–58

    Article  PubMed  CAS  Google Scholar 

  • Herzog BA, Ott PA, Dittrich MT, Quast S, Karulin AY, Kalbacher H et al (2004) Increased in vivo frequency of IA-2 peptide-reactive IFNgamma+/IL-4- T cells in type 1 diabetic subjects. J Autoimmun 23(1):45–54

    Article  PubMed  CAS  Google Scholar 

  • Hesse MD, Karulin AY, Boehm BO, Lehmann PV, Tary-Lehmann M (2001) A T cell clone’s avidity is a function of its activation state. J Immunol 167(3):1353–1361

    PubMed  CAS  Google Scholar 

  • Hofstetter HH, Targoni OS, Karulin AY, Forsthuber TG, Tary-Lehmann M, Lehmann PV (2005) Does the frequency and avidity spectrum of the neuroantigen-specific T cells in the blood mirror the autoimmune process in the central nervous system of mice undergoing experimental allergic encephalomyelitis? J Immunol 174(8):4598–4605

    PubMed  CAS  Google Scholar 

  • Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G (2012) Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology 1(5):670–686

    Article  PubMed  Google Scholar 

  • Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR et al (2001) Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 19(1):145–156

    PubMed  CAS  Google Scholar 

  • Karulin AY, Hesse MD, Tary-Lehmann M, Lehmann PV (2000) Single-cytokine-producing CD4 memory cells predominate in type 1 and type 2 immunity. J Immunol 164(4):1862–1872

    PubMed  CAS  Google Scholar 

  • Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361(19):1838–1847

    Google Scholar 

  • Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C et al (2009) Immunogenicity and antitumor effects of vaccination with peptide vaccine ± granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 15(4):1443–1451

    Article  PubMed  CAS  Google Scholar 

  • Kreher CR, Dittrich MT, Guerkov R, Boehm BO, Tary-Lehmann M (2003) CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J Immunol Methods 278(1–2):79–93

    Article  PubMed  CAS  Google Scholar 

  • Kuerten S, Nowacki TM, Kleen TO, Asaad RJ, Lehmann PV, Tary-Lehmann M (2008) Dissociated production of perforin, granzyme B, and IFN-gamma by HIV-specific CD8(+) cells in HIV infection. AIDS Res Hum Retroviruses 24(1):62–71

    Article  PubMed  CAS  Google Scholar 

  • Kuerten S, Batoulis H, Recks MS, Kraracsony E, Zhang W, Subbramanian RA et al (2012) Resting of cryopreserved PBMC does not in general benefit the performance of antigen-specific T cell ELISPOT assays. Cells 1(3):409–427

    Article  CAS  Google Scholar 

  • Lehmann PV, Zhang W (2012) Unique strengths of ELISPOT for T cell diagnostics. Methods Mol Biol 792:3–23

    Article  PubMed  CAS  Google Scholar 

  • Lehmann PV, Forsthuber T, Miller A, Sercarz EE (1992) Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358(6382):155–157

    Article  PubMed  CAS  Google Scholar 

  • Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G (1993) Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 14(5):203–208

    Article  PubMed  CAS  Google Scholar 

  • Lonsdorf AS, Kuekrek H, Stern BV, Boehm BO, Lehmann PV, Tary-Lehmann M (2003) Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol 171(8):3941–3946

    PubMed  CAS  Google Scholar 

  • Lopez MN, Pereda C, Segal G, Munoz L, Aguilera R, Gonzalez FE et al (2009) Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol 27(6):945–952

    Article  PubMed  CAS  Google Scholar 

  • Mohan JF, Unanue ER (2012) Unconventional recognition of peptides by T cells and the implications for autoimmunity. Nat Rev Immunol 12(10):721–728

    Article  PubMed  CAS  Google Scholar 

  • Mosmann TR, Kobie JJ, Lee FE, Quataert SA (2009) T helper cytokine patterns: defined subsets, random expression, and external modulation. Immunol Res 45(2–3):173–184

    Article  PubMed  CAS  Google Scholar 

  • Nowacki TM, Kuerten S, Zhang W, Shive CL, Kreher CR, Boehm BO et al (2007) Granzyme B production distinguishes recently activated CD8(+) memory cells from resting memory cells. Cell Immunol 247(1):36–48

    Article  PubMed  CAS  Google Scholar 

  • Quast S, Zhang W, Shive C, Kovalovski D, Ott PA, Herzog BA et al (2005) IL-2 absorption affects IFN-gamma and IL-5, but not IL-4 producing memory T cells in double color cytokine ELISPOT assays. Cell Immunol 237(1):28–36

    Article  PubMed  CAS  Google Scholar 

  • Ramachandran H, Laux J, Moldovan I, Caspell P, Lehmann PV (2012) Optimal thawing of cryopreserved peripheral blood mononuclear cells for use in high-throughput human immune monitoring studies. Cells 1(3):313–324

    Article  Google Scholar 

  • Rininsland FH, Helms T, Asaad RJ, Boehm BO, Tary-Lehmann M (2000) Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity. J Immunol Methods 240(1–2):143–155

    Article  PubMed  CAS  Google Scholar 

  • Schlingmann TR, Rininsland FH, Bartholomae WC, Kuekrek H, Lehmann PV, Tary-Lehmann M (2009a) Vaccination with tumor cells pulsed with foreign peptide induces immunity to the tumor itself. Clin Immunol 133(1):45–51

    Article  PubMed  CAS  Google Scholar 

  • Schlingmann TR, Shive CL, Targoni OS, Tary-Lehmann M, Lehmann PV (2009b) Increased per cell IFN-gamma productivity indicates recent in vivo activation of T cells. Cell Immunol 258(2):131–137

    Article  PubMed  CAS  Google Scholar 

  • Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C et al (2007) Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 13(21):6386–6395

    Article  PubMed  CAS  Google Scholar 

  • Stern BV, Boehm BO, Tary-Lehmann M (2002) Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity. J Immunol 168(12):6099–6105

    PubMed  CAS  Google Scholar 

  • Targoni OS, Lehmann PV (1998) Endogenous myelin basic protein inactivates the high avidity T cell repertoire. J Exp Med 187(12):2055–2063

    Article  PubMed  CAS  Google Scholar 

  • Thakur A, Pedersen LE, Jungersen G (2012) Immune markers and correlates of protection for vaccine induced immune responses. Vaccine 30(33):4907–4920

    Article  PubMed  CAS  Google Scholar 

  • Tian J, Lehmann PV, Kaufman DL (1997) Determinant spreading of T helper cell 2 (Th2) responses to pancreatic islet autoantigens. J Exp Med 186(12):2039–2043

    Article  PubMed  CAS  Google Scholar 

  • Tigno-Aranjuez JT, Jaini R, Tuohy VK, Lehmann PV, Tary-Lehmann M (2009a) Encephalitogenicity of complete Freund’s adjuvant relative to CpG is linked to induction of Th17 cells. J Immunol 183(9):5654–5661

    Article  PubMed  CAS  Google Scholar 

  • Tigno-Aranjuez JT, Lehmann PV, Tary-Lehmann M (2009b) Dissociated induction of cytotoxicity and DTH by CFA and CpG. J Immunother 32(4):389–398

    Article  PubMed  CAS  Google Scholar 

  • Zhang W, Lehmann PV (2012) Objective, user-independent ELISPOT data analysis based on scientifically validated principles. Methods Mol Biol 792:155–171

    Article  PubMed  CAS  Google Scholar 

  • Zhang W, Caspell R, Karulin AY, Ahmad M, Haicheur N, Abdelsalam A et al (2009) ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring–even in hands of ELISPOT-inexperienced investigators. J Immunotoxicol 6(4):227–234

    Article  PubMed  CAS  Google Scholar 

  • Zhang W, Moldovan I, Targoni OS, Subbramanian RA, Lehmann PV (2012) How much of virus-specific CD8 T cell reactivity is detected with a peptide pool when compared to individual peptides? Viruses 4(11):2636–2649

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cellular Technology Limited, Shaker Heights, Ohio, 44122, USA

    Paul V. Lehmann & Srividya Sundararaman

Authors
  1. Paul V. Lehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Srividya Sundararaman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Srividya Sundararaman .

Editor information

Editors and Affiliations

  1. Department of Pathology, University of Pittsburgh Medical Center, 3550 Terrace Street Scaife Hal, Pittsburgh, 15213, Pennsylvania, USA

    Michael R. Shurin

  2. , Clinical Cooperation Unit Dermato-Oncolo, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg, 69120, Germany

    Viktor Umansky

  3. , SAIC-Frederick, Inc., National Cancer Institute at Frederick, Post Office B, Frederick, 21702, Maryland, USA

    Anatoli Malyguine

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Lehmann, P.V., Sundararaman, S. (2013). When Results of T cell Immune Monitoring Match/Do Not Match Clinical Outcomes of Tumor Vaccine Trials: What More Could and Should We Measure?. In: Shurin, M., Umansky, V., Malyguine, A. (eds) The Tumor Immunoenvironment. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6217-6_32

Download citation

Publish with us

Policies and ethics

Search

Navigation